Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1186 | Endoscopic management according to standard of care Wiki | 0.71 |
| drug797 | Cloth Face Mask Wiki | 0.71 |
| drug1385 | Graded exercise test Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D002761 | Cholangitis NIH | 1.00 |
| D015209 | Cholangitis, Sclerosing NIH | 0.71 |
| D008105 | Liver Cirrhosis, Biliary NIH | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D041781 | Jaundice, Obstructive NIH | 0.71 |
| D007565 | Jaundice, NIH | 0.50 |
| D018281 | Cholangiocarcinoma NIH | 0.50 |
| D054990 | Idiopathic Pulmonary Fibrosis NIH | 0.50 |
| D010190 | Pancreatic Neoplasms NIH | 0.41 |
| D005355 | Fibrosis NIH | 0.20 |
| D011658 | Pulmonary Fibrosis NIH | 0.18 |
| D011014 | Pneumonia NIH | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002613 | Biliary cirrhosis HPO | 0.71 |
| HP:0030153 | Cholangiocarcinoma HPO | 0.50 |
| HP:0000952 | Jaundice HPO | 0.50 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002894 | Neoplasm of the pancreas HPO | 0.41 |
| HP:0002206 | Pulmonary fibrosis HPO | 0.18 |
| HP:0002090 | Pneumonia HPO | 0.04 |
Navigate: Correlations HPO
There are 2 clinical trials
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT
Description: The SUVmax in a lung or liver with known IPF, COVID19 pneumonia, or PSC respectively will be compared to the SUVmax in a known healthy lung/liver. It is expected that the SUV max, which is a measurement of the maximum value of radiopharmaceutical uptake within the region of interest (ROI) in IPF, COVID19 pneumonia, and PSC will be higher than the SUV max in the healthy lung/liver.
Measure: SUV max comparison : IPF versus Healthy Lung, PSC versus Healthy Liver, COVID19 versus Healthy Lung Time: an estimated average of 2 hoursDescription: Blood samples for blood time-activity measurements taken at 1, 3, 5, 10, 30, and 60 minutes after tracer injection for tracer kinetic analysis. Tracer kinetic analysis shows radiopharmaceutical distribution from the blood to the tissues over time.
Measure: Time Activity Measurements Time: an estimated average of 1 hoursDescription: EKG data, vital signs and laboratory data collected before IV injection of [18F]FP-R01-MG-F2 and after completion of the scan will allow the investigators to evaluate the safety and tolerability of the radiopharmaceutical. This will be measured as the number of patients who successfully completed the study.
Measure: Incidence of Study Completion (Safety and Tolerability) Time: an estimated average of 2 hoursIn this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.
Description: Investigators will report the baseline demographic data (age, gender, nationality) of all patients.
Measure: Age, gender, nationality Time: 3 monthsDescription: Investigators will report the baseline data clinical data (indication for procedure, status of SARS-CoV-2 infection) of all patients.
Measure: Indication for procedure, status of SARS-CoV-2 infection Time: 3 monthsDescription: Investigators will report the baseline laboratory data (complete blood count and liver functions tests) of all patients.
Measure: Complete blood count and liver functions tests Time: 3 monthsDescription: Investigators will report the procedure related complications.
Measure: procedure related complications Time: 3 monthsDescription: Investigators will report wether the precautions lead to increase timing of the procedure
Measure: Effect of COVID-19 precautions on procedure time Time: 3 monthsDescription: Investigators will report wether the precautions affected staff number (increased or decreased)
Measure: Effect of COVID-19 precautions on staff number Time: 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports